Skip to content
Get the Balanced News app for a better experience!
The Balanced News Logo
Analytics
The Balanced News Logo

Stay Balanced, Stay Informed

Menu
  • Browse News
  • Underreported Stories
  • Curated Feeds
  • Insights
  • Analytics
  • Our Writers
  • About Us
  • Download App
Learn
  • How It Works
  • Bias Detection
  • Lens Score
  • Source Bias Checker
  • Accountability
  • Custom Feeds
Newsroom
  • Writers & Analysts
  • About TBN
  • Editorial Standards
  • Corrections Policy
  • Our Partners
  • Insights
Socials
  • Youtube
  • Instagram
  • X
  • Facebook
News Categories
  • Trending
  • Politics
  • Sports
  • Business
  • Tech
  • Entertainment
  • Health
  • Science
  • Crime
  • Lifestyle
  • National
  • International
  • Good News
  • Crypto

Get Our App

Available for iOS and Android


LensFeedsInsightsAnalyticsTrendingGood NewsSportsPoliticsBusinessCrimeTechEntertainmentHealthNationalInternational

© 2026 The Balanced News. All rights reserved.

About UsEditorial StandardsCorrectionsHelp & SupportPrivacy PolicyTerms & Conditions
Supreme Court Critiques High Medicine Markups Amid Government Price Regulation Efforts

Categories

Categories

Related Coverage

Select a news story to see related coverage from other media outlets.

Related Coverage

Select a news story to see related coverage from other media outlets.

  1. Home
  2. /
  3. Business

Supreme Court Critiques High Medicine Markups Amid Government Price Regulation Efforts

Analysed 27 Oct 2026·11 sources analysed·Mumbai, India·Business
Supreme Court Critiques High Medicine Markups Amid Government Price Regulation EffortsPreviousNext

The Supreme Court of India has criticized hospitals for charging patients excessively high prices for medicines, with markups ranging from 170% to 1,000%, describing such practices as "dacoity." The government has acknowledged challenges in regulating drug prices, especially in the private healthcare sector, and recently capped trade margins on 137 anti-cancer drugs at 30%. However, experts note that high manufacturer prices and limited competition may limit patient savings. The debate highlights the need to balance affordability with sustained investment in healthcare infrastructure and services.

Political Bias
0%64%36%
Sentiment
54%
TBN's observations

First-hand measurement across 11 sources

We measured how 11 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 64%, Right 36%). Overall sentiment is neutral (54/100). Lens Score 42/100.

Outlets measured: economictimes, mint, hindustantimes, thestatesman, indiatoday, theprint, theprint, businessstandard, and 3 more. See how each one headlined and framed the same story in the source comparison below.

AI analysis of 11 sources · Published under editorial oversight by The Balanced News
Analysed 27 Oct 2026· How this analysis is produced· Editorial standards· Corrections

AI Analysis

Political bias across 11 sources
● Left 0%● Center 64%● Right 36%

All 1 outlets scored close to centre on political lean. The real divergence here is in emphasis, not lean — compare the headlines below to see how each outlet chose to frame the same facts.

Sentiment — Neutral (54/100)

Sentiment ranged widely across outlets — from 32/100 to 75/100 — a sign the coverage itself was contested, not just reported.

Coverage timeline

economictimes broke this story on 25 Oct, 07:24 am. Other outlets followed.

25 Oct, 07:24 am11 sources · 2 days27 Oct, 07:19 pm
AI analysis by the TBN Bias Engine · beat methodology byMrunal Wange· Business & Economy Editor· editorial standards byOjas Kale
← Previous
M K Sons Fine Jewels Raises Rs 82.62 Crore Ahead of Rs 275.4 Crore IPO Launch
Next →
Eastern Coalfields Ltd Opens Geotechnical Laboratory to Enhance Mine Safety
  1. 1
    economictimes25 Oct, 07:24 am
    Rs 1 lakh to Rs 30,000: Cancer immunotherapy gets cheaper, but will patients get the price benefit?
  2. 2
    thefinancialexpress25 Oct, 12:36 pm
    Drugmakers can raise cancer drug prices despite trade margin cap
  3. 3
    indianexpress26 Oct, 03:38 am
    Cancer drug price caps: Why India needs more than price control
  4. 4
    businessstandard26 Oct, 04:43 pm
    Pricing pain points
  5. 5
    theprint27 Oct, 05:42 am
    Centre's trade margin cap for cancer drugs has its limits. Not all 137 listed meds may become affordable
  6. 6
    theprint27 Oct, 09:06 am
    Drug price caps can't stop at cancer medicines. India needs to regulate pharma margins
  7. 7
    indiatoday27 Oct, 11:18 am
    Hospital charged drug dealer Rs 1.3 lakh for injection he could buy for Rs 11,000: SC
  8. 8
    thestatesman27 Oct, 12:30 pm
    'Where does the money go?': Supreme Court questions how hospitals can charge 100-200 times the cost of medicines
  9. 9
    hindustantimes27 Oct, 12:32 pm
    As health care needs grow, balance affordability with investment
  10. 10
    mint27 Oct, 05:38 pm
    NPPA slashes cancer drug MRPs by up to 93 ; Thiotepa cut by 72,921 Mint
  11. 11
    economictimes27 Oct, 07:19 pm
    Cancer drug price cuts leave costly brands untouched

Who's involved

Institutions and figures named across source coverage.

Government
governmentNational Pharmaceutical Pricing AuthorityGovernment of India
Political
Bharatiya Janata Party
Judiciary
Supreme Court of India

Story context

Category
Business
Location
Mumbai, India
Sources analysed
11
Last analysed
27 Oct 2026
Key entities
CancerIndian rupeeIndiaMedicinePharmaceutical industryMedicationPatentLakhNational Pharmaceutical Pricing AuthorityPalbociclibNew DelhiDacoity